Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation

转分化 癌症研究 生物 腺癌 PI3K/AKT/mTOR通路 奥西默替尼 蛋白激酶B 癌症 信号转导 细胞 细胞生物学 遗传学 ROS1型
作者
Álvaro Quintanal-Villalonga,Hirokazu Taniguchi,Yingqian A. Zhan,Maysun Hasan,Shweta S. Chavan,Fanli Meng,Fathema Uddin,Viola Allaj,Parvathy Manoj,Nisargbhai Shah,Joseph M. Chan,Metamia Ciampricotti,Andrew Chow,Michael Offin,Jordana Ray-Kirton,Jacklynn D. Egger,Umesh Bhanot,Irina Linkov,Marina Asher,Michael H. A. Roehrl
出处
期刊:Journal of Hematology & Oncology [BioMed Central]
卷期号:14 (1) 被引量:51
标识
DOI:10.1186/s13045-021-01186-z
摘要

Abstract Background Lineage plasticity, the ability to transdifferentiate among distinct phenotypic identities, facilitates therapeutic resistance in cancer. In lung adenocarcinomas (LUADs), this phenomenon includes small cell and squamous cell (LUSC) histologic transformation in the context of acquired resistance to targeted inhibition of driver mutations. LUAD-to-LUSC transdifferentiation, occurring in up to 9% of EGFR -mutant patients relapsed on osimertinib, is associated with notably poor prognosis. We hypothesized that multi-parameter profiling of the components of mixed histology (LUAD/LUSC) tumors could provide insight into factors licensing lineage plasticity between these histologies. Methods We performed genomic, epigenomics, transcriptomics and protein analyses of microdissected LUAD and LUSC components from mixed histology tumors, pre-/post-transformation tumors and reference non-transformed LUAD and LUSC samples. We validated our findings through genetic manipulation of preclinical models in vitro and in vivo and performed patient-derived xenograft (PDX) treatments to validate potential therapeutic targets in a LUAD PDX model acquiring LUSC features after osimertinib treatment. Results Our data suggest that LUSC transdifferentiation is primarily driven by transcriptional reprogramming rather than mutational events. We observed consistent relative upregulation of PI3K/AKT, MYC and PRC2 pathway genes. Concurrent activation of PI3K/AKT and MYC induced squamous features in EGFR -mutant LUAD preclinical models. Pharmacologic inhibition of EZH1/2 in combination with osimertinib prevented relapse with squamous-features in an EGFR-mutant patient-derived xenograft model, and inhibition of EZH1/2 or PI3K/AKT signaling re-sensitized resistant squamous-like tumors to osimertinib. Conclusions Our findings provide the first comprehensive molecular characterization of LUSC transdifferentiation, suggesting putative drivers and potential therapeutic targets to constrain or prevent lineage plasticity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
斯文如娆发布了新的文献求助30
2秒前
只争朝夕的应助被可妍昇采纳,获得10
2秒前
2秒前
CipherSage的应助被qyt采纳,获得10
3秒前
3秒前
3秒前
3秒前
奋斗若风完成签到,获得积分10
5秒前
zjq4302完成签到,获得积分10
5秒前
ZZZZZZZZ完成签到,获得积分10
5秒前
5秒前
XINGCHEN完成签到 ,获得积分10
5秒前
6秒前
6秒前
Xxxy完成签到 ,获得积分10
6秒前
6秒前
7秒前
wjw完成签到,获得积分10
8秒前
风信子完成签到,获得积分10
8秒前
8秒前
8秒前
苏丽妃完成签到 ,获得积分10
8秒前
情怀的应助被jc哥采纳,获得10
8秒前
Zz发布了新的文献求助20
8秒前
Elige完成签到,获得积分10
8秒前
孙淳完成签到,获得积分10
8秒前
yan发布了新的文献求助10
8秒前
所所的应助被liquidwy采纳,获得10
9秒前
汉堡包的应助被白白采纳,获得10
9秒前
俞佳美发布了新的文献求助10
9秒前
ylva完成签到,获得积分10
9秒前
plemon完成签到,获得积分10
10秒前
圆圆完成签到,获得积分10
10秒前
unqiue的应助被荼蘼采纳,获得10
10秒前
元吉的应助被荼蘼采纳,获得10
10秒前
Ximilu发布了新的文献求助10
10秒前
我是老大的应助被荼蘼采纳,获得10
10秒前
heady发布了新的文献求助10
10秒前
明理的千筹发布了新的文献求助100
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180927
求助须知:如何正确求助?哪些是违规求助? 9570973
关于积分的说明 21815578
捐赠科研通 7777227
什么是DOI,文献DOI怎么找? 3433367
关于科研通互助平台的介绍 2557621
邀请新用户注册赠送积分活动 2479346